This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

L. Kristin Newby, MD, MHS; Eric D. Peterson, MD, MPH

JAMA. 2007;297:1823-1825.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Despite an arsenal of medicines and revascularization options, millions of individuals experience acute and chronic anginal symptoms daily. Imperative upon physicians is a responsibility not only to extend life and prevent major life-threatening complications but also to improve the quality of life. To that end, clinical trials of new treatment modalities for ischemic heart disease and the adoption of new therapies into practice should weigh these twin goals.

Ranolazine represents a novel type of antianginal therapy thought to reduce symptoms by blocking intracellular sodium and calcium overload accompanying myocardial ischemia.^1-2 Randomized trials demonstrated that ranolazine was effective in reducing angina symptoms and increasing exercise time to angina or ST-segment depression when compared with standard therapeutic agents, such as atenolol, diltiazem, and amlodipine without hemodynamic adverse effects.^{1, 3-4} However, these trials were limited in size and duration, and were not powered to . . . [Full Text of this Article]

Author Affiliations: Division of Cardiovascular Medicine and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non-ST-Elevation Acute Coronary Syndromes: The MERLIN-TIMI 36 Randomized Trial
, , , , , , , , , , and
JAMA. ;297():1775-1783.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ranolazine Does Not Alter Cardiovascular Prognosis in Patients with Angina
JWatch Emergency Med. 2007;2007:1-1.
FULL TEXT  

Ranolazine to Treat Acute Coronary Syndromes?
Journal Watch Cardiology 2007;2007:1-1.
FULL TEXT